Here are four things to know:
1. Mr. Kennedy joined Histogenics in 2013 as senior vice president of technical operations.
2. Before that, he served as the executive vice president, research and development, at Mascoma, a biofuel company.
3. He has also held several senior leadership roles in technical operations at Genzyme, a biopharmaceutical company.
4. Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal market.
More articles on devices:
Smith & Nephew Q2 revenue up 5%: 8 things to know
5 key notes on NuVasive’s 10% share growth yesterday — What it means going forward
SeaSpine Q2 revenue down 6% in first report as independent company: 6 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
